Advice

Following a full submission.

Rotigotine (Neupro) is not recommended for use within NHS Scotland for the treatment of the signs and symptoms of early-stage idiopathic Parkinson’s disease as monotherapy (i.e. without levodopa).

Rotigotine was superior to placebo in two randomised controlled trials. However, in one active comparator study non-inferiority to another non-ergolinic dopamine agonist comparator was not shown. The economic case has not been demonstrated.

Download detailed advice46KB (PDF)

Download

Medicine details

Medicine name:
rotigotine 2mg/24 hours, 4mg/24 hours, 6mg/24 hours, 8mg/24 hours transdermal patch (Neupro)
SMC ID:
289/06
Indication:
Early-stage idiopathic Parkinson' s disease as monotherapy
Pharmaceutical company
Schwarz Pharma Ltd
BNF chapter
Central nervous system
Submission type
Full
Status
Not recommended
Date advice published
07 August 2006